(CRNX) Crinetics Pharmaceuticals - Ratings and Ratios

Crinetics Pharmaceuticals, Inc. is a clinical-stage biotech company with a sharp focus on rare endocrine disorders and endocrine-related cancers. Their pipeline is built around oral, nonpeptide therapeutics—a smart move given the challenges of peptide drugs.

Their lead candidate, paltusotine, is a selective somatostatin receptor type 2 agonist. It’s in Phase 3 for acromegaly and Phase 2 for carcinoid syndrome. Paltusotine’s oral delivery is a big advantage here, as most somatostatin analogs are injectable.

CRN04894 is another promising candidate. It targets the ACTH receptor and has completed Phase 1 for diseases like congenital adrenal hyperplasia and Cushing’s disease. This is a significant area of unmet need.

Beyond these, Crinetics is exploring PTH receptor antagonists for hyperparathyroidism and hypercalcemia. They’re also looking at somatostatin receptor type 3 agonists for polycystic kidney disease and TSH receptor antagonists for Graves’ disease and thyroid eye disease. Their GLP-1 and GIP nonpeptide agonists for diabetes and obesity round out a diverse pipeline.

Crinetics has been around since 2008 and is based in San Diego. Their market cap is around $3.7 billion, with a price-to-book ratio of 4.48. The company is pre-revenue, so traditional P/E metrics don’t apply yet.

https://www.crinetics.com